Correction to “Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsenin Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses”
{"title":"Correction to “Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsenin Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses”","authors":"","doi":"10.1002/cpdd.1620","DOIUrl":null,"url":null,"abstract":"<p>Han K, Theodore D, McMullen G, et al. Preclinical and phase 1 assessment of antisense oligonucleotide bepirovirsen in hepatitis B virus–transgenic mice and healthy human volunteers: support for clinical dose selection and evaluation of safety, tolerability, and pharmacokinetics of single and multiple doses. <i>Clin Pharmacol Drug Dev</i>. 2022;11:1191–1202. https://doi.org/10.1002/cpdd.1154</p><p>In the article cited above, the authors have determined that an error was present in the Funding section. The corrected Funding section is shown below.</p><p>Funding</p><p>This phase 1 first-in-human study was, at the time of the trial, fully sponsored and funded by Ionis Pharmaceuticals, Inc. (ISIS 50538-CS1). The study has since been acquired by GSK (Study 213725). The preclinical in vitro and in vivo studies (3470-144) were sponsored and funded by Ionis Pharmaceuticals Inc. and supported by a grant from the National Institutes of Health to Stefan Wieland (AI094409).</p><p>We apologize for this error.</p>","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 3","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1002/cpdd.1620","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology in Drug Development","FirstCategoryId":"3","ListUrlMain":"https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1620","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Han K, Theodore D, McMullen G, et al. Preclinical and phase 1 assessment of antisense oligonucleotide bepirovirsen in hepatitis B virus–transgenic mice and healthy human volunteers: support for clinical dose selection and evaluation of safety, tolerability, and pharmacokinetics of single and multiple doses. Clin Pharmacol Drug Dev. 2022;11:1191–1202. https://doi.org/10.1002/cpdd.1154
In the article cited above, the authors have determined that an error was present in the Funding section. The corrected Funding section is shown below.
Funding
This phase 1 first-in-human study was, at the time of the trial, fully sponsored and funded by Ionis Pharmaceuticals, Inc. (ISIS 50538-CS1). The study has since been acquired by GSK (Study 213725). The preclinical in vitro and in vivo studies (3470-144) were sponsored and funded by Ionis Pharmaceuticals Inc. and supported by a grant from the National Institutes of Health to Stefan Wieland (AI094409).
期刊介绍：
Clinical Pharmacology in Drug Development is an international, peer-reviewed, online publication focused on publishing high-quality clinical pharmacology studies in drug development which are primarily (but not exclusively) performed in early development phases in healthy subjects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
